Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

    ... in the United States in 4 cohorts: (1) lower-risk MDS ( International Prognostic Scoring System [IPSS] low and intermediate-1 risk), with and ...

    Research Article last updated 09/19/2016 - 11:05am.

  2. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... PURPOSE: This international phase III, randomized, placebo -controlled, double-blind ... in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic ...

    Research Article last updated 07/18/2016 - 10:30am.

  3. Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes

    ... intermediate-risk disease as classified by the Revised International Prognostic Scoring System (IPSS-R) or those with higher-risk disease for ...

    Research Article last updated 07/18/2016 - 11:26am.

  4. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the Europ

    ... conditioning and 34% and 27% had intermediate-2 and high international prognostic scoring system (IPSS) scores. At time of HSCT, 32% of patients ...

    Research Article last updated 07/18/2016 - 11:22am.

  5. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... clinical and biological activity in patients with International Prognostic Scoring System (IPSS) lower-risk (low- and intermediate-1-risk) ...

    Research Article last updated 06/23/2016 - 10:17am.

  6. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis

    ... World Health Organization, French-American-British, or International Prognostic Scoring System (IPSS) criteria. Outcomes included erythroid ...

    Research Article last updated 06/23/2016 - 9:14am.

  7. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study

    ... The median age was 73 years, and 79% had revised International Prognostic Scoring System (IPSS-R) risk scores of intermediate or lower. ...

    Research Article last updated 06/07/2016 - 11:03am.

  8. Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes

    ... (MDSs), like cytogenetic stratification of the revised international prognostic scoring system (IPSS-R) or monosomal karyotype, may also improve ...

    Research Article last updated 05/22/2014 - 9:03am.

  9. Personalized medicine for MDS

    ... determining therapy.  Key-Findings: -The International Prognostic Scoring System (IPSS) helps to risk stratify MDS patients into ...

    Research Review last updated 05/02/2016 - 9:44am.

  10. Myelodysplastic syndromes: Contemporary review and how we treat

    ... in MDS. Conventional prognostication is by the revised International prognostic scoring system (IPSS-R) with additional adverse prognosis ...

    Research Article last updated 04/29/2016 - 1:05pm.